Alexion currently has nine lead development programs underway with its five highly innovative therapeutic candidates, including asfotase alfa, a first-in-class targeted enzyme replacement therapy in Phase 2 clinical trials for Hypophosphatasia (HPP). HPP is an inherited and life-threatening ultra-rare metabolic disorder that leads to progressive damage to multiple vital organs, including destruction and deformity of bones. Read more
Alexion is pleased to announce two recent additions to our leadership team, Martin Mackay as Executive Vice President and Global Head of R&D, and Saqib Islam as Senior Vice President, Chief Strategy and Portfolio Officer. We are excited to broaden and strengthen our executive leadership team as we prepare for continued growth to serve patients worldwide. Read more
Alexion has a global operations platform that now serves patients in nearly 50 countries. Every day, we strive to make a life-transforming impact in the lives of patients with severe and life-threatening disorders that are also ultra-rare. See their stories